Lorviqua 100mg (Lorlatinib Tablet) 100mg

Lorviqua 100mg (lorlatinib) is a prescription tablet used for certain types of non-small cell lung cancer. This oral medication targets ALK-positive tumors. Store at room temperature in a dry place. Not for use without medical supervision.

Strength

100mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Pfizer

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lorviqua 100mg is prescribed for adults with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. It is used when cancer has spread to other parts of the body or has not responded to prior ALK inhibitor therapy. The medication works by blocking signals that help cancer cells grow. It is typically given after other treatments have been tried.

Side Effects

Lorviqua 100mg may help slow the progression of cancer cells in the body. Some users report improved energy levels or reduced symptoms related to lung cancer. Individual responses vary, and effects depend on medical history and treatment plan. Regular monitoring by a healthcare provider is recommended.

Precautions & Warnings

Keep Lorviqua 100mg in its original packaging away from moisture and direct sunlight. Store at room temperature and keep out of reach of children. Do not crush, split, or chew the tablets. If a dose is missed, follow your doctor’s guidance—do not take extra doses to compensate. Report any unusual symptoms to your healthcare provider promptly.

Avoid Interactions

Lorviqua may interact with other medications, including strong CYP3A inducers or inhibitors. Avoid grapefruit products while taking this medication. Certain supplements, herbal products, and over-the-counter drugs may also affect how Lorviqua works. Always inform your doctor about all medications and supplements you are using.

References

Frequently Asked Questions

Lorviqua 100mg is used to treat adults with ALK-positive non-small cell lung cancer that has spread or not responded to prior therapy.

Store Lorviqua 100mg at room temperature in a dry place, away from moisture and direct sunlight.

No, avoid grapefruit and grapefruit juice while taking Lorviqua as it may affect how the medication works.

If you miss a dose, contact your healthcare provider for guidance—do not take extra doses to make up for it.

Lorviqua 100mg is not a cure but may help slow the progression of ALK-positive lung cancer.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.